Based on various in vivo and in vitro cardiac hypertrophy models, we clearly identified cardiac TRAF6 as a positive regulator of functional and structural cardiac remodelling via activating TAK1-JNK1/2/p38 signalling. Here, MAP3K7 is linked to cardiac hypertrophy.